Safety of Oral Echinacea Preparations: Systematic Review and Meta-Analysis in the Context of Therapeutic Benefit.

IF 2.1 4区 医学 Q3 CHEMISTRY, MEDICINAL
Planta medica Pub Date : 2026-11-12 DOI:10.1055/a-2992-1199
Mercedes Ogal, Merlin Willcox, Rudolf Bauer, Sebastian L Johnston, Samo Kreft, Anthony Booker, Andreas Schapowal, Danielle Roux, Giuseppe Gancitano, Rainer Stange
{"title":"Safety of Oral Echinacea Preparations: Systematic Review and Meta-Analysis in the Context of Therapeutic Benefit.","authors":"Mercedes Ogal, Merlin Willcox, Rudolf Bauer, Sebastian L Johnston, Samo Kreft, Anthony Booker, Andreas Schapowal, Danielle Roux, Giuseppe Gancitano, Rainer Stange","doi":"10.1055/a-2992-1199","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Recent literature has assessed the potential of <i>Echinacea</i> products to reduce respiratory tract infections (RTIs) and antibiotic use but has not comprehensively evaluated safety within a risk-benefit framework. Our systematic review and meta-analysis reviewed relevant databases for adverse events (AEs) in clinical trials comparing oral <i>Echinacea</i> (all species and preparations) with placebo, active, or no-treatment groups. AEs were classified by System Organ Class (SOC) and compared with individual case safety reports (ICRs) from EudraVigilance (EVDAS).</p><p><strong>Abstract: </strong>Across 48 clinical studies (<i>N</i> = 10,115), 2,396 AEs were reported. AE occurrence was lower in <i>Echinacea</i> groups compared with any control (22.7% vs. 24.8%, <i>p</i> = 0.014) and to placebo control only (29.1% vs. 32.3%; <i>p</i> = 0.005). In therapeutic settings, after excluding pressed juice formulations, <i>Echinacea</i> significantly reduced AEs by up to 21.1% (19.8% vs. 25.1%; <i>p</i> < 0.0001). Preventive studies in healthy participants showed comparable AE rates between <i>Echinacea</i> and control groups (21.3% vs. 22.3%; <i>p</i> = 0.411). Serious AEs (SAEs) accounted for 0.09% and 0.08% of events for <i>Echinacea</i> and any control, respectively; no fatal SAEs were reported.</p><p><strong>Abstract: </strong>Spontaneous EVDAS reports mostly concerned gastrointestinal (17.7%), general (13.1%), and nervous system disorders (10.3%, e.g., headache), whereas skin and subcutaneous tissue events (16.1%) were less prominent in clinical trials, which predominantly investigated high-quality pharmaceutical extracts.</p><p><strong>Abstract: </strong>Principally, oral <i>Echinacea</i> products demonstrate a high level of safety, with preparation-dependent qualitative differences. Pharmaceutical-grade ethanolic extracts showed further reductions in AEs versus control, possibly reflecting clinical efficacy and supporting positive risk-benefit evaluation for RTI management and antibiotic stewardship.</p>","PeriodicalId":20127,"journal":{"name":"Planta medica","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Planta medica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2992-1199","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract: Recent literature has assessed the potential of Echinacea products to reduce respiratory tract infections (RTIs) and antibiotic use but has not comprehensively evaluated safety within a risk-benefit framework. Our systematic review and meta-analysis reviewed relevant databases for adverse events (AEs) in clinical trials comparing oral Echinacea (all species and preparations) with placebo, active, or no-treatment groups. AEs were classified by System Organ Class (SOC) and compared with individual case safety reports (ICRs) from EudraVigilance (EVDAS).

Abstract: Across 48 clinical studies (N = 10,115), 2,396 AEs were reported. AE occurrence was lower in Echinacea groups compared with any control (22.7% vs. 24.8%, p = 0.014) and to placebo control only (29.1% vs. 32.3%; p = 0.005). In therapeutic settings, after excluding pressed juice formulations, Echinacea significantly reduced AEs by up to 21.1% (19.8% vs. 25.1%; p < 0.0001). Preventive studies in healthy participants showed comparable AE rates between Echinacea and control groups (21.3% vs. 22.3%; p = 0.411). Serious AEs (SAEs) accounted for 0.09% and 0.08% of events for Echinacea and any control, respectively; no fatal SAEs were reported.

Abstract: Spontaneous EVDAS reports mostly concerned gastrointestinal (17.7%), general (13.1%), and nervous system disorders (10.3%, e.g., headache), whereas skin and subcutaneous tissue events (16.1%) were less prominent in clinical trials, which predominantly investigated high-quality pharmaceutical extracts.

Abstract: Principally, oral Echinacea products demonstrate a high level of safety, with preparation-dependent qualitative differences. Pharmaceutical-grade ethanolic extracts showed further reductions in AEs versus control, possibly reflecting clinical efficacy and supporting positive risk-benefit evaluation for RTI management and antibiotic stewardship.

口服紫锥菊制剂的安全性:疗效方面的系统评价和荟萃分析。
最近的文献评估了紫锥菊产品减少呼吸道感染(RTIs)和抗生素使用的潜力,但没有在风险-收益框架内全面评估安全性。我们的系统综述和荟萃分析回顾了有关临床试验中不良事件(ae)的相关数据库,比较口服紫锥菊(所有品种和制剂)与安慰剂组、有效组和无治疗组。根据系统器官分类(SOC)对ae进行分类,并与EudraVigilance (EVDAS)的个案安全报告(ICRs)进行比较。在48项临床研究(N = 10,115)中,报告了2,396例ae。紫锥菊组的AE发生率低于任何对照组(22.7%比24.8%,p = 0.014)和安慰剂组(29.1%比32.3%,p = 0.005)。在治疗环境中,排除压榨果汁制剂后,紫锥菊显著降低ae高达21.1% (19.8% vs. 25.1%; p < 0.0001)。健康参与者的预防研究显示,紫锥菊组和对照组的AE发生率相当(21.3%比22.3%;p = 0.411)。严重不良反应(sae)分别占紫锥菊组和任何对照组的0.09%和0.08%;没有致命的急性呼吸道感染报告。自发性EVDAS报告主要涉及胃肠道(17.7%),一般(13.1%)和神经系统疾病(10.3%,例如头痛),而皮肤和皮下组织事件(16.1%)在临床试验中不太突出,主要研究高质量的药物提取物。总的来说,口服紫锥菊产品显示出高水平的安全性,与制剂相关的质量差异。与对照组相比,药用级乙醇提取物显示ae进一步降低,可能反映了临床疗效,并支持对RTI管理和抗生素管理的积极风险-收益评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Planta medica
Planta medica 医学-药学
CiteScore
5.10
自引率
3.70%
发文量
101
审稿时长
1.8 months
期刊介绍: Planta Medica is one of the leading international journals in the field of natural products – including marine organisms, fungi as well as micro-organisms – and medicinal plants. Planta Medica accepts original research papers, reviews, minireviews and perspectives from researchers worldwide. The journal publishes 18 issues per year. The following areas of medicinal plants and natural product research are covered: -Biological and Pharmacological Activities -Natural Product Chemistry & Analytical Studies -Pharmacokinetic Investigations -Formulation and Delivery Systems of Natural Products. The journal explicitly encourages the submission of chemically characterized extracts.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书